GlaxoSmithKline plc (GSK) Price Target Cut to GBX 1,760 by Analysts at Berenberg Bank

GlaxoSmithKline plc (LON:GSK) had its price target reduced by investment analysts at Berenberg Bank from GBX 1,835 ($24.21) to GBX 1,760 ($23.23) in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 29.65% from the stock’s previous close.

GSK has been the topic of a number of other reports. J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 1,570 ($20.72) price target on shares of GlaxoSmithKline plc in a research note on Monday, October 2nd. Liberum Capital reissued a “buy” rating and set a GBX 1,760 ($23.23) price target on shares of GlaxoSmithKline plc in a research note on Wednesday, October 25th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price target on GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.38) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Finally, Beaufort Securities reissued a “buy” rating and set a GBX 1,800 ($23.75) price target on shares of GlaxoSmithKline plc in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of GBX 1,619.75 ($21.37).

GlaxoSmithKline plc (LON:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. The firm had revenue of GBX 784.30 billion for the quarter.

ILLEGAL ACTIVITY WARNING: This article was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/11/02/glaxosmithkline-plc-gsk-price-target-cut-to-gbx-1760-by-analysts-at-berenberg-bank.html.

In other news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was purchased at an average price of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average price of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). In the last 90 days, insiders have bought 1,574 shares of company stock valued at $2,398,888.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply